Beta-blockers will continue to fall out of favor for hypertension

January 2013

Beta-blockers will continue to fall out of favor for hypertension...especially atenolol.

Beta-blockers seem to prevent fewer CV events in patients with hypertension than other BP meds...despite similar BP lowering.

Atenolol has a particularly bad reputation...because most hypertension trials evaluating cardiovascular risk used atenolol.

Get concise advice on drug therapy, plus unlimited access to CE

Pharmacist's Letter membership benefits include:

12 issues every year — what you need to know and do, right now
Quick, practical reference charts and tools
Comprehensive CE library to meet license renewal and state requirements
Multiple course formats including live webinars, podcasts, and CE-in-the-Letter to match your learning style
Plus much more!

Choose the right tier for your needs today.

Already a subscriber? Log in

Volume pricing available. Get a quote